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INTRODUCTION
The value of oxypertine in the treatment of chronic schizophrenia has been the subject of several clinical trials, the results of which have been reviewed recently (Skarbek and Jacobsen, 1965). In particular a comparison of the effects of oxypertine and trifluoperazine in thirty-five schizophrenic women revealed statistically sig nificant differences between the drugs, oxy pertine showing a tendency to activate the withdrawn cases (Calwell, Jacobsen and Skar bek, 1964 ).An opportunity arose to study five of these patients again under controlled con ditions, and it was felt that this would be useful for two reasons. First, it would show whether the response to oxypertine was repeatable, as the patients had meanwhile resumed their previous treatment. Secondly, by a detailed examination over an extended period, using a battery of tests and flexible dosage, a more exact delineation of the optimal symptomatic response to oxypertine could be made.
PATIENTS AND METHOD
The first trial had taken place in 1962, and the second study was made in the period October, 1964 to February, 1965 . The five women selected for this further investigation had all shown improvement on oxypertine as meas ured by the Wing Scales A and B (Wing, 1961) . The details of the five patients are given in Table I .
It is clear that to change these patients' treatment again and subject them to the detailed scrutiny of a battery of assessments might in itself produce an effect on their symptoms and behaviour. The first step, therefore, was to continue with their current drug therapy in a new capsule form. This made it easy to change the treatment by using other drugs in identical capsules. During this transition period weekly assessments were begun, using three scales: Following a week on trifluoperazine, the treatment was changed to placebo for three weeks, followed by seventeen weeks on oxy pertine, during which period the dosage was adjusted by the psychiatrist in order to obtain maximal improvement. The details of the dosages used are given in Table II .
Following the major period on oxypertine, dummy capsules were again substituted for two These a priori contrasts can be compared with the error variance to give separate F ratios, even in the absence of an overall significant difference between the treatment means. Where the latter is significant the means for the different treat.. ment periods can be compared a posteriori using the studentized range statistic. This has been done in the case of the total Wing A score, see Table   XII .
It is seen that the significant differences are only to be found with the Wing A scores.
There is a marked difference between placebo and active treatments, and between oxypertine and trifluoperazine. There is also a difference between the two placebo periods, and it is the second period which is the worse, almost as though there was a rebound after the oxypertine period. The two spells on trifluoperazine do not differ significantly. These findings are confirmed by the a posteriori comparisons in Fig. 2 .
The differences on the total Wing A scores are seen to be due chiefly to differences in Flat ness and Incongruity of Affect, and to a lesser extent to Poverty of Speech and to Coherent
Delusions. There were no significant differences found in Incoherence of Speech. In the earlier trial the significant differences were found in the area of Poverty of Speech and some of the Wing B items.
There were no adverse effects encountered during the study, except for one episode of vomiting during the transitional period and a There seems no doubt that these patients on scales which are chiefly concerned with ward have reproduced the significant improvement behaviour. Note: these probability levels should be interpreted with caution, see text.
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Fzo. 2.â€"A posteriori comparison of treatment means on Wing Scale Aâ€"total score.
